Man Group
FULC icon

Man Group’s Fulcrum Therapeutics FULC Stock Holding History

Man Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,119
Closed -$354K – 2436
2026
Q1 		$354K Buy
46,119
+30,866
+202% +$286K ﹤0.01% 2173
2025
Q4 		$173K Buy
+15,253
New +$155K ﹤0.01% 2148
2024
Q4 		– Sell
-48,324
Closed -$173K – 2054
2024
Q3 		$173K Buy
+48,324
New +$359K ﹤0.01% 1875
2024
Q2 		– Sell
-102,226
Closed -$965K – 2097
2024
Q1 		$965K Buy
102,226
+7,609
+8% +$67.9K ﹤0.01% 1551
2023
Q4 		$639K Buy
+94,617
New +$420K ﹤0.01% 1600
2023
Q1 		– Sell
-96,152
Closed -$700K – 2137
2022
Q4 		$700K Buy
96,152
+10,394
+12% +$67.8K ﹤0.01% 1420
2022
Q3 		$694K Buy
+85,758
New +$614K ﹤0.01% 1407
2022
Q2 		– Hold
0
– – – 1493

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Man Group's FULC Position: Q2 2026 in Review

Man Group sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 46,119 shares — an estimated $354K sold.

Man Group first reported a position in FULC in Q3 2022 and held it in 7 quarters. The position peaked at $965K in Q1 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Man Group reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 46,119 Fulcrum Therapeutics shares in Q2 2026, an estimated $354K.
  • Man Group first reported a position in Fulcrum Therapeutics in Q3 2022 and held it in 7 quarters.
  • Man Group's Fulcrum Therapeutics position peaked at $965K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.